Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Janssen,Daratumumab IV (with bortezomib and dexamethasone),"Multiple myeloma, relapsed or refractory, 2nd line",Daratumumab IV (with bortezomib and dexamethasone),,Oncology Agents and Immunosuppressants
